{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T14:21:13Z","timestamp":1775744473946,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s10072-023-07082-3","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T08:02:44Z","timestamp":1697184164000},"page":"1233-1242","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Rituximab as a sole steroid-sparing agent in generalized myasthenia gravis: Long-term outcomes"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6889-8043","authenticated-orcid":false,"given":"Zinovia-Maria","family":"Kefalopoulou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitra","family":"Veltsista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Germeni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimosthenis","family":"Lykouras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eirini","family":"Tsiamaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Chroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,13]]},"reference":[{"key":"7082_CR1","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE (2016) Myasthenia Gravis. N Engl J Med 375:2570\u20132581. https:\/\/doi.org\/10.1056\/NEJMra1602678","journal-title":"N Engl J Med"},{"issue":"4","key":"7082_CR2","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1007\/s10072-021-05077-6","volume":"42","author":"C Rodolico","year":"2021","unstructured":"Rodolico C, Nicocia G, Damato V, Antonini G, Liguori R, Evoli A (2021) Benefit and danger from immunotherapy in myasthenia gravis. Neurol Sci 42(4):1367\u20131375. https:\/\/doi.org\/10.1007\/s10072-021-05077-6","journal-title":"Neurol Sci"},{"key":"7082_CR3","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G et al (2021) International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology 96:114\u2013122. https:\/\/doi.org\/10.1212\/WNL.0000000000011124","journal-title":"Neurology"},{"key":"7082_CR4","doi-asserted-by":"publisher","first-page":"175628561774913","DOI":"10.1177\/1756285617749134","volume":"11","author":"R Mantegazza","year":"2018","unstructured":"Mantegazza R, Antozzi C (2018) When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord 11:1756285617749134. https:\/\/doi.org\/10.1177\/1756285617749134","journal-title":"Ther Adv Neurol Disord"},{"key":"7082_CR5","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/acn3.51492","volume":"9","author":"E Cortes-Vicente","year":"2022","unstructured":"Cortes-Vicente E, Alvarez-Velasco R, Pla-Junca F et al (2022) Drug-refractory myasthenia gravis: Clinical characteristics, treatments, and outcome. Ann Clin Transl Neurol 9:122\u2013131. https:\/\/doi.org\/10.1002\/acn3.51492","journal-title":"Ann Clin Transl Neurol"},{"key":"7082_CR6","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia Gravis: Subgroup Classification and Therapeutic Strategies. Lancet Neurol 14:1023\u20131036. https:\/\/doi.org\/10.1016\/S1474-4422(15)00145-3","journal-title":"Lancet Neurol"},{"key":"7082_CR7","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","volume":"89","author":"MK Hehir","year":"2017","unstructured":"Hehir MK, Hobson-Webb LD, Benatar M et al (2017) Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review. Neurology 89:1069\u20131077. https:\/\/doi.org\/10.1212\/WNL.0000000000004341","journal-title":"Neurology"},{"key":"7082_CR8","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/mus.26107","volume":"58","author":"J Morren","year":"2018","unstructured":"Morren J, Li Y (2018) Myasthenia gravis with muscle-specific tyrosine kinase antibodies: A narrative review. Muscle Nerve 58:344\u2013358. https:\/\/doi.org\/10.1002\/mus.26107","journal-title":"Muscle Nerve"},{"key":"7082_CR9","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1111\/ene.14391","volume":"27","author":"A Dos Santos","year":"2020","unstructured":"Dos Santos A, Noury JB, Genestet S et al (2020) Efficacy and safety of rituximab in myasthenia gravis: a French multicentre real-life study. Eur J Neurol 27:2277\u20132285. https:\/\/doi.org\/10.1111\/ene.14391","journal-title":"Eur J Neurol"},{"key":"7082_CR10","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1136\/jnnp-2019-322606","volume":"91","author":"V Di Stefano","year":"2020","unstructured":"Di Stefano V, Lupica A, Rispoli MG, Di Muzio A, Brighina F, Rodolico C (2020) Rituximab in AChR subtype of myasthenia gravis: systematic review. J Neurol Neurosurg Psychiatry 91:392\u2013395. https:\/\/doi.org\/10.1136\/jnnp-2019-322606","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7082_CR11","doi-asserted-by":"publisher","first-page":"736190","DOI":"10.3389\/fneur.2021.736190","volume":"12","author":"C Zhao","year":"2021","unstructured":"Zhao C, Pu M, Chen D et al (2021) Effectiveness and Safety of Rituximab for Refractory Myasthenia Gravis: A Systematic Review and Single-Arm Meta-Analysis. Front Neurol 12:736190. https:\/\/doi.org\/10.3389\/fneur.2021.736190","journal-title":"Front Neurol"},{"issue":"4","key":"7082_CR12","doi-asserted-by":"publisher","first-page":"e376","DOI":"10.1212\/WNL.0000000000013121","volume":"98","author":"RJ Nowak","year":"2021","unstructured":"Nowak RJ, Coffey CS, Goldstein JM et al (2021) Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study. Neurology 98(4):e376\u2013e389. https:\/\/doi.org\/10.1212\/WNL.0000000000013121","journal-title":"Neurology"},{"key":"7082_CR13","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1080\/14712598.2021.1889509","volume":"21","author":"ZA Siddiqi","year":"2021","unstructured":"Siddiqi ZA, Khan W, Hussain FS (2021) Rituximab in Myasthenia Gravis - Where do we stand? Expert Opin Biol Ther 21:1013\u20131023. https:\/\/doi.org\/10.1080\/14712598.2021.1889509","journal-title":"Expert Opin Biol Ther"},{"key":"7082_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12883-017-0857-7","volume":"17","author":"L Wang","year":"2017","unstructured":"Wang L, Zhang Y, He M (2017) Clinical predictors for the prognosis of myasthenia gravis. BMC Neurol 17:77. https:\/\/doi.org\/10.1186\/s12883-017-0857-7","journal-title":"BMC Neurol"},{"issue":"1","key":"7082_CR15","doi-asserted-by":"publisher","first-page":"e0190425","DOI":"10.1371\/journal.pone.0190425","volume":"13","author":"AB Memon","year":"2018","unstructured":"Memon AB, Javed A, Caon C, Srivastawa S, Bao F, Bernitsas E et al (2018) Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases. PLoS ONE 13(1):e0190425. https:\/\/doi.org\/10.1371\/journal.pone.0190425","journal-title":"PLoS ONE"},{"key":"7082_CR16","first-page":"18","volume":"30","author":"E Chroni","year":"2021","unstructured":"Chroni E, Veltsista D, Malefaki S, Dimitriou E (2021) Optimum treatment strategy for myasthenia gravis: a single-center experience. Arch Clin Neurol 30:18\u201326","journal-title":"Arch Clin Neurol"},{"key":"7082_CR17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/wnl.55.1.16","volume":"55","author":"A Jaretzki 3rd","year":"2000","unstructured":"Jaretzki A 3rd, Barohn RJ, Ernstoff RM et al (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurol 55:16\u201323. https:\/\/doi.org\/10.1212\/wnl.55.1.16","journal-title":"Neurol"},{"key":"7082_CR18","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association (2013) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310:2191\u20132194. https:\/\/doi.org\/10.1001\/jama.2013.281053","journal-title":"JAMA"},{"key":"7082_CR19","unstructured":"National Cancer Institute (U.S.) (2009) Common terminology criteria for adverse events (CTCAE). Rev. edn. Bethesda, Md.: U.S. Dept. of Health and Human Services, National Institutes of Health, National Cancer Institute"},{"key":"7082_CR20","doi-asserted-by":"publisher","first-page":"204209862098568","DOI":"10.1177\/2042098620985687","volume":"12","author":"F Barlow-Pay","year":"2021","unstructured":"Barlow-Pay F, Htut TW, Khezrian M, Myint PK (2021) Systematic review of immunosuppressant guidelines in the COVID-19 pandemic. Ther Adv Drug Saf 12:2042098620985687. https:\/\/doi.org\/10.1177\/2042098620985687","journal-title":"Ther Adv Drug Saf"},{"key":"7082_CR21","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1212\/WNL.0000000000009566","volume":"94","author":"AC Guidon","year":"2020","unstructured":"Guidon AC, Amato AA (2020) COVID-19 and neuromuscular disorders. Neurology 94:959\u2013969. https:\/\/doi.org\/10.1212\/WNL.0000000000009566","journal-title":"Neurology"},{"key":"7082_CR22","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s13760-021-01808-w","volume":"122","author":"KC Spiliopoulos","year":"2022","unstructured":"Spiliopoulos KC, Kasdaglis N, Veltsista D, Lykouras D, Lagadinou M, Chroni E (2022) Teleneurology in a center for neuromuscular diseases during the COVID-19 pandemic. Acta Neurol Belg 122:721\u2013724. https:\/\/doi.org\/10.1007\/s13760-021-01808-w","journal-title":"Acta Neurol Belg"},{"key":"7082_CR23","doi-asserted-by":"publisher","first-page":"116648","DOI":"10.1016\/j.jns.2019.116648","volume":"410","author":"J Morren","year":"2020","unstructured":"Morren J, Li Y (2020) Maintenance immunosuppression in myasthenia gravis, an update. J Neurol Sci 410:116648. https:\/\/doi.org\/10.1016\/j.jns.2019.116648","journal-title":"J Neurol Sci"},{"key":"7082_CR24","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1001\/jamaneurol.2020.0851","volume":"77","author":"S Brauner","year":"2020","unstructured":"Brauner S, Eriksson-Dufva A, Hietala MA, Frisell T, Press R, Piehl F (2020) Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis. JAMA Neurol 77:974\u2013981. https:\/\/doi.org\/10.1001\/jamaneurol.2020.0851","journal-title":"JAMA Neurol"},{"issue":"11","key":"7082_CR25","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","volume":"79","author":"F Piehl","year":"2022","unstructured":"Piehl F, Eriksson-Dufva A, Budzianowska A et al (2022) Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis: The RINOMAX Randomized Clinical Trial. JAMA Neurol 79(11):1105\u20131112. https:\/\/doi.org\/10.1001\/jamaneurol.2022.2887","journal-title":"JAMA Neurol"},{"issue":"1","key":"7082_CR26","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10072-020-04528-w","volume":"42","author":"BK Vitturi","year":"2021","unstructured":"Vitturi BK, Kim AIH, Mitre LP, Pellegrinelli A, Valerio BCO (2021) Social, professional and neuropsychiatric outcomes in patients with myasthenia gravis. Neurol Sci 42(1):167\u2013173. https:\/\/doi.org\/10.1007\/s10072-020-04528-w","journal-title":"Neurol Sci"},{"key":"7082_CR27","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/acn3.564","volume":"5","author":"E Cortes-Vicente","year":"2018","unstructured":"Cortes-Vicente E, Rojas-Garcia R, Diaz-Manera J et al (2018) The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis. Ann Clin Transl Neurol 5:710\u2013716. https:\/\/doi.org\/10.1002\/acn3.564","journal-title":"Ann Clin Transl Neurol"},{"key":"7082_CR28","doi-asserted-by":"publisher","unstructured":"Litchman T, Roy B, Kumar A, Sharma A, Njike V, Nowak RJ (2020) Differential response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients: a single-center retrospective study. J Neurol Sci 411:116690. https:\/\/doi.org\/10.1016\/j.jns.2020.116690","DOI":"10.1016\/j.jns.2020.116690"},{"key":"7082_CR29","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.nmd.2016.12.004","volume":"27","author":"V Afanasiev","year":"2017","unstructured":"Afanasiev V, Demeret S, Bolgert F, Eymard B, Laforet P, Benveniste O (2017) Resistant myasthenia gravis and rituximab: A monocentric retrospective study of 28 patients. Neuromuscul Disord 27:251\u2013258. https:\/\/doi.org\/10.1016\/j.nmd.2016.12.004","journal-title":"Neuromuscul Disord"},{"key":"7082_CR30","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/mus.27521","volume":"65","author":"D Veltsista","year":"2022","unstructured":"Veltsista D, Kefalopoulou Z, Tzartos J, Chroni E (2022) Autoantibody profile in myasthenia gravis patients with a refractory phase. Muscle Nerve 65:607\u2013611. https:\/\/doi.org\/10.1002\/mus.27521","journal-title":"Muscle Nerve"},{"key":"7082_CR31","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1002\/mus.27393","volume":"64","author":"CT Doughty","year":"2021","unstructured":"Doughty CT, Suh J, David WS, Amato AA, Guidon AC (2021) Retrospective analysis of safety and outcomes of rituximab for myasthenia gravis in patients >\/=65 years old. Muscle Nerve 64:651\u2013656. https:\/\/doi.org\/10.1002\/mus.27393","journal-title":"Muscle Nerve"},{"key":"7082_CR32","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jocn.2020.11.043","volume":"85","author":"T Li","year":"2021","unstructured":"Li T, Zhang GQ, Li Y et al (2021) Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: A meta-analysis. J Clin Neurosci 85:6\u201312. https:\/\/doi.org\/10.1016\/j.jocn.2020.11.043","journal-title":"J Clin Neurosci"},{"key":"7082_CR33","doi-asserted-by":"publisher","first-page":"e136471","DOI":"10.1172\/jci.insight.136471","volume":"5","author":"R Jiang","year":"2020","unstructured":"Jiang R, Fichtner ML, Hoehn KB et al (2020) Single-cell repertoire tracing identifies rituximab-resistant B cells during myasthenia gravis relapses. JCI Insight 5:e136471. https:\/\/doi.org\/10.1172\/jci.insight.136471","journal-title":"JCI Insight"},{"key":"7082_CR34","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1007\/s13311-021-01006-9","volume":"18","author":"C Ruetsch-Chelli","year":"2021","unstructured":"Ruetsch-Chelli C, Bresch S, Seitz-Polski B, Rosenthal A, Desnuelle C, Cohen M et al (2021) Memory B Cells Predict Relapse in Rituximab-Treated Myasthenia Gravis. Neurotherapeutics 18:938\u2013948. https:\/\/doi.org\/10.1007\/s13311-021-01006-9","journal-title":"Neurotherapeutics"},{"key":"7082_CR35","doi-asserted-by":"publisher","first-page":"720","DOI":"10.5607\/en.2019.28.6.720","volume":"28","author":"YG Min","year":"2019","unstructured":"Min YG, Park C, Kwon YN, Shin JY, Sung JJ, Hong YH (2019) B Cell Immunophenotyping and Transcriptional Profiles of Memory B Cells in Patients with Myasthenia Gravis. Exp Neurobiol 28:720\u2013726. https:\/\/doi.org\/10.5607\/en.2019.28.6.720","journal-title":"Exp Neurobiol"},{"key":"7082_CR36","doi-asserted-by":"publisher","first-page":"802559","DOI":"10.3389\/fneur.2022.802559","volume":"13","author":"Y Kim","year":"2022","unstructured":"Kim Y, Li X, Huang Y et al (2022) COVID-19 Outcomes in Myasthenia Gravis Patients: Analysis From Electronic Health Records in the United States. Front Neurol 13:802559. https:\/\/doi.org\/10.3389\/fneur.2022.802559","journal-title":"Front Neurol"},{"key":"7082_CR37","doi-asserted-by":"publisher","first-page":"107140","DOI":"10.1016\/j.clineuro.2022.107140","volume":"213","author":"AS Abbas","year":"2022","unstructured":"Abbas AS, Hardy N, Ghozy S et al (2022) Characteristics, treatment, and outcomes of Myasthenia Gravis in COVID-19 patients: A systematic review. Clin Neurol Neurosurg 213:107140. https:\/\/doi.org\/10.1016\/j.clineuro.2022.107140","journal-title":"Clin Neurol Neurosurg"},{"issue":"4","key":"7082_CR38","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1007\/s10072-021-05823-w","volume":"43","author":"CL Rodrigues","year":"2022","unstructured":"Rodrigues CL, de Freitas HC, Lima PRO, de Oliveira Junior PH, Fernandes JMA, D\u2019Almeida JAC et al (2022) Myasthenia gravis exacerbation and myasthenic crisis associated with COVID-19: case series and literature review. Neurol Sci 43(4):2271\u20132276. https:\/\/doi.org\/10.1007\/s10072-021-05823-w","journal-title":"Neurol Sci"},{"key":"7082_CR39","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s40265-022-01726-y","volume":"82","author":"D Menon","year":"2022","unstructured":"Menon D, Bril V (2022) Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals. Drugs 82:865\u2013887. https:\/\/doi.org\/10.1007\/s40265-022-01726-y","journal-title":"Drugs"},{"key":"7082_CR40","doi-asserted-by":"publisher","first-page":"175628642110654","DOI":"10.1177\/17562864211065406","volume":"14","author":"C Schneider-Gold","year":"2021","unstructured":"Schneider-Gold C, Gilhus NE (2021) Advances and challenges in the treatment of myasthenia gravis. Ther Adv Neurol Disord 14:17562864211065406. https:\/\/doi.org\/10.1177\/17562864211065406","journal-title":"Ther Adv Neurol Disord"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-07082-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-023-07082-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-07082-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T02:04:20Z","timestamp":1707530660000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-023-07082-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["7082"],"URL":"https:\/\/doi.org\/10.1007\/s10072-023-07082-3","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,13]]},"assertion":[{"value":"14 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We confirm that we have read the Journal\u2019s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors have no conflicts to disclose related to this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}